Diffusion of certain guidelines, addressing all the elements with the use of LAI antipsychotics, will enhance clinicians’ perceived competence. It’ll also help to increase the percentage of patients to whom LAI antipsychotics will probably be presented by psychiatrists as a therapeutic selection. The objective of those recommendations is to propose a prescription framework to clinicians for the usage of a specific formulation of antipsychotics (LAI) in diverse therapeutic indications and specific clinical situations. The aim is to permit clinicians to offer one of the most suitable pharmaceutical methods to the individuals and to facilitate the use of LAI antipsychotics in clinical practice. The recommendations presented here from a consensus-based recommendations methodology (Formal Consensus Guidelines) arebased on scientific data plus the consensus of a panel of professionals.MethodsQuestionnaire developmentInitially, we performed an analysis plus a literature critique concerning the indications plus the use of LAI antipsychotics. A literature search using the keyword phrases “antipsychotic”, “neuroleptic”, “first-generation antipsychotic”, “atypical antipsychotic”, “second-generation antipsychotic”, “long-acting injectable”, “depot”, “depot neuroleptic” was performed in PubMed and EMBASE to seek out all of the relevant studies published. Additional references were identified from http:www.fda.gov and http: www.ema.europa.eu. Data from all of these sources was discussed and an overview with the current proof has been graded and summarized working with the French National Authority for Wellness (HAS) “levels of evidence” criteria [16]. Following this initially step, the scientific committee (PML, LS, MA, Computer, SG, SL) produced a questionnaire consisting of 32 queries that covered 539 therapeutic selections. The 32 inquiries were regrouped into three places PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310042 that have been judged as important: Target-population: Description on the distinctive indications of your LAI antipsychotics and with the most suitable period in the illness to introduce the therapy. Prescription and use: Option on the molecule, techniques of introduction, specific methods according to the psychiatric disorder or comorbidities, and treatment monitoring. Specific population: Use of LAI antipsychotics in pregnant ladies, elderly individuals, subjects inside a precarious scenario, and subjects obtaining to be treated within a prison establishment. This questionnaire was created to be completed by an experts’ panel. The time needed for its administration was estimated at about 3 hours. At the time of improvement, each of the LAI antipsychotics accessible in France had been proposed as therapeutic choices (Table 1). They were regrouped into two categories: Long-acting injectable first-generation antipsychotics (LAI FGA). Long-acting injectable second-generation antipsychotics (LAI SGA). This artificial separation FGASGA will not be consensual as a consequence of their heterogeneous profiles of efficacyLlorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page 3 ofTable 1 LAI antipsychotics available in France (when the survey was completed)LAI second-generation antipsychotics LAI first-generation antipsychotics Risperidone microsphere Olanzapine (RS)-Alprenolol web pamoate Haloperidol decanoate Zuclopenthixol decanoate Flupentixol decanoate Fluphenazine decanoate Pipotiazine palmitateNote: as paliperidone palmitate had a marketing and advertising authorization date following the development of those guidelines, it could not be taken into account.Professional selectionThe Scientific Committee (Appendix 1) sel.